Tremelimumab (Ticilimumab) 是一种完全人源化的单克隆抗体，对细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 具有特异性，可用于转移性黑色素瘤研究。
1化学性质
CAS号：745013-59-6
储存条件：Please store the product under the recommended conditions in the Certificate of Analysis.
运输方式：冰袋运输，根据产品的不同，可能会有相应调整。
2参考文献
[1] No authors listed. Tremelimumab
[2] Masatoshi Kudo. Hepatobiliary Surg Nutr. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
[3] Do-Youn Oh, et al. Lancet Gastroenterol Hepatol. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
[4] Robin Kate Kelley, et al. J Clin Oncol. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
[5] Jonathan W Goldman, et al. Lancet Oncol. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
关键词：
cas
tremelimumab
曲美